A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/19 (2006.01) A61P 25/06 (2006.01) A61P 25/08 (2006.01) A61P 25/24 (2006.01)
Patent
CA 2341803
A new oral polymeric controlled release formulation suitable for the once-a- day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.
Bollinger J. Daniel
Cheskin Howard S.
Dutta Sandeep
Engh Kevin R.
Poska Richard P.
Abbott Laboratories
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Controlled release formulation of divalproex sodium does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled release formulation of divalproex sodium, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled release formulation of divalproex sodium will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1929023